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Skeletal development is controlled by extracellular 
matrix synthesis and deposition in combination 
with a complex regulatory network of cellular 
differentiation. Understanding these processes has 
been aided by mapping human disease genes, which 
have revealed fundamental insights into a number of the biological 
mechanisms underlying skeletogenesis. To date, more than 450 
skeletal conditions have been identified and classified based on 
molecular, biochemical and/or radiographic criteria.[1] One such 
disorder is Beukes hip dysplasia (BHD) (OMIM #142669), a rare 
autosomal dominant condition that was originally identified in 
a large, multigeneration South African (SA) family of European 
descent.[2] BHD is characterised by severe progressive degenerative 
osteoarthritis (OA) of the hip joint in early adulthood. The condition 
is unique in that the underlying dysplasia and subsequent OA are 
confined to this region. Affected individuals are of normal stature and 
have no associated health problems. As described in detail previously, 
symptoms of hip joint discomfort usually develop in infancy or later 
childhood, but in a single individual initial presentation was as late 
as 35 years of age.[2] Phenotypic expression is age-related and variable 
in severity. The penetrance of this disorder is incomplete and has 
been estimated to be 80%. The earliest primary radiographic features 
of BHD include bilateral shortening and broadening of the femoral 
neck, delayed appearance of the secondary ossification centre, coxa 
vara, displacement of the femoral head in the acetabulum, and 
overgrowth of the greater trochanters. Following onset of symptoms, 
the characteristic signs of secondary OA (including bone sclerosis, 
cyst formation and narrowing of the joint space) develop and the 
joint deteriorates rapidly. We have previously mapped the BHD locus 
to a 3.34 Mb region of chromosome 4q35.[3] This locus has not been 
linked to other forms of familial acetabular dysplasia, indicating that 
BHD is a distinct disorder.[4,5]
To reduce the complexity of disease gene identification, we fine-
mapped the chromosome 4q35 locus with polymorphic DNA markers. 
A combined Sanger and next-generation sequencing approach was 
used to screen coding and invariant splice-site sequences located 
within the linked interval for candidate pathogenic mutations. The 
development of ‘next-generation sequencing’ has accelerated the 
identification of disease-causing variants. This technology enables 
millions of DNA fragments covering all known protein coding and 
splice-site sequences of multiple individuals to be sequenced in a 
single experiment. This is typically achieved following a targeted 
enrichment reaction in which a sheared genomic DNA sample 
is hybridised to a pool of RNA baits that are complementary to 
the genomic region of interest. Through the application of this 
technology, we were able to confirm the presence of a single-
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Background. Beukes hip dysplasia (BHD) is an autosomal dominant disorder of variable penetrance that was originally identified in a large 
South African family of European origin. BHD is characterised by bilateral dysmorphism of the proximal femur, which results in severe 
degenerative osteoarthropathy. Previous studies mapped the disorder to a 3.34 Mb region on chromosome 4q35.
Objective. To fine-map the BHD locus and identify the disease-causing mutation by direct sequencing.
Results. The linked BHD allele was refined to 1.33 Mb, reducing the number of candidate genes from 25 to 16. Analysis of protein coding 
and invariant splice-site sequences in three distantly related individuals identified a single-candidate disease-causing variant c.868T>C within 
exon 8 of the ubiquitin-fold modifier 1 (Ufm1)-specific peptidase 2 gene, UFSP2. The presence of this unique mutation was confirmed in all 
17 affected members of the BHD family who were genotyped. The mutation segregated with the BHD phenotype in the extended family with 
a two-point (single marker) LOD score of 10.4 (θ = 0.0 and 80% penetrance). The mutation predicts the substitution of a highly conserved 
amino acid, p.Tyr290His, in the encoded protein. In vitro functional assays performed using purified recombinant wild-type and mutant UFSP2 
protein demonstrated that the BHD mutation abolishes UFSP2-mediated C-terminal cleavage of its substrate, Ufm1.
Conclusion. We report a unique UFSP2 mutation that segregates with the BHD phenotype. The predicted amino acid substitution 
inactivates UFSP2 proteolytic function, thus implicating the ubiquitin-fold modifier 1 cascade in this form of severe hip osteoarthropathy. 
The facile polymerase chain reaction-based assay we describe could be used to confirm the diagnosis of BHD, or for presymptomatic testing 
of members of the extended BHD family.
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candidate disease-causing variant within the BHD locus, which we 
subsequently characterised in vitro.
Methods
Archived DNA samples (extracted from blood samples obtained 
following informed consent for the purpose of molecular genetic 
analysis) were available from earlier investigations of the family, 
as reported previously.[3] A standard salting-out protocol was used 
to extract DNA from peripheral blood lymphocytes of 40 family 
members.
Fine-mapping the BHD locus
Microsatellite sizing and restriction fragment polymorphism 
genotyping of markers D4S1535 (Chr4: 185 235 750 - 185 236 098) 
and rs7663196 (Chr4: 186 570 521) was performed on members of 
the BHD family (Applied Biosystems, UK). Primer sequences are 
available on request. Two-point LOD scores were calculated using 
Linkage v5.1 (http://www.jurgott.org/linkage/LinkagePC.html).
Mutation screening and bioinformatic analysis
Comprehensive mutation screening of coding and flanking intron 
bases of three genes within the linked locus, CASP3, LRP2BP and 
UFSP2, was initially undertaken by Sanger sequencing (further 
details available on request). With the ubiquitous availability of 
next-generation sequencing, three distantly related individuals 
(VII:9, VII:10 and VI:24) were then selected for exome sequencing. 
Approximately 3 μg of genomic DNA was sheared using a Covaris 
S2 (Covaris Inc., USA) before standard whole-genome library 
preparation was performed, following the manufacturer’s protocols 
throughout (Agilent Technologies, UK). Two enrichment polymerase 
chain reaction (PCR) reactions were necessary to obtain the required 
mass of genomic library for enrichment hybridisation, which was 
carried out using a SureSelect All Exon V5 (no UTRs) bait set. 
Final exome-enriched libraries were confirmed using an Agilent 
Bioanalyser prior to being pooled in equimolar concentrations. 
The pool was sequenced on a HiSeq2500 across three lanes of rapid 
mode flow cells in a run configuration that generated paired-end 
100-bp reads (Illumina Inc., USA). Raw data were demultiplexed 
and converted to FASTQ.gz format using CASAVA v1.8.2. To analyse 
each individual, sequence reads were first aligned to an indexed 
human reference genome (hg19) using bwa v0.6.2. Duplicate reads 
were removed using Picard v1.85 (http://picard.sourceforge.net), and 
SAM/BAM file processing was performed using samtools v0.1.18 
(http://samtools.sourceforge.net). GATKLite v2.3-4 was used to 
perform indel realignment, base quality recalibration, variant calling 
with the UnifiedGenotyper and read-depth analysis (http://www.
broadinstitute.org/gatk/index.php). Variant call format files were 
annotated with position, frequency (incorporating dbSNP and the 
Fig. 1. The BHD pedigree, with disease-linked alleles highlighted in red. The smallest disease interval was identified in individual VI:24. Symbols containing a 
question mark (?) are probably non-penetrant carriers of the BHD allele. The marker order from top to bottom is: D4S1554, D4S1535, D4S171, UFSP2 c.868T>C, 
D4S2924, rs7663196 and D4S3051. The genotypes for D4S1554, D4S171, D4S2924 and D4S3051 are as previously published.[3] The UFSP2 c.868 ‘C’ allele is 
notated ‘1’ and the ‘T’ allele as ‘2’ (displayed in bold). The pedigree has been compressed to show only those individuals who contributed to the linkage analysis.
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ESP5400 dataset) and in silico variant effect predictions using Alamut 
Batch v1.1.5 (http://www.interactive-biosoftware.com/software/
alamut/overview). Interpretation of the annotated variant dataset 
was aided using AgileExomeFilter (http://dna.leeds.ac.uk/agile)[6] and 
the variant-decision support software Alamut Visual. To assess exon 
copy number variation, FishingCNV v2.1 (http://sourceforge.net/
projects/fishingcnv/) was used to compare the sequenced read depth 
of BHD individuals to a pooled reference control comprising 65 BHD 
disease-free patients.
Molecular assay for UFSP2  
mutation analysis
A 341-bp PCR amplicon spanning the UFSP2 c.868T>C mutation was 
gene rated using forward primer dCATTAAACATAATTCGGGAGCA 
and reverse primer dTCTGCACCATGAGGTAACAAA. Each PCR 
reaction consisted of 1 μL of 15 ng/μL DNA, 2.5 μL of 10× PCR 
buffer, 1 μL of 50 mM MgCl2, 1 μL of 10 mM dNTPs, 0.5  μL of 
BIOTAQTM DNA polymerase (5 U/μL), 17 μL of nuclease-free water, 
1 μL of 10 μM forward primer and 1 μL of 10 μM reverse primer 
(Bioline Reagents Ltd., UK and Eurogentec Ltd., UK). Thermocycling 
conditions consisted of 95oC for 3 minutes followed by 36 cycles 
of 95oC for 30 seconds, 55oC for 45 seconds, 72oC for 45 seconds, 
and a final extension at 72oC for 10 minutes. The UFSP2 c.868T>C 
mutation introduced an NdeI (CATATG) restriction site that was 
detected by incubating PCR products with NdeI for 1 hour at 37oC 
and, if the mutation was present, generated 219-bp and 122-bp PCR 
fragments (NEB, UK). PCR products were resolved by tris-borate-
EDTA agarose gel electrophoresis.
Functional analysis of the  
UFSP2 mutation
A previously described expression construct for mouse UFSP2 
(NM_138668.2) was modified to incorporate the heterologous BHD 
mutation (c.844T>C, p.Tyr282His).[7] The wild-type (WT) (UFSP2 
WT) and mutant (UFSP2 BHD) constructs together with a GST-
Ufm1-HA construct were expressed in Escherichia coli and purified. 
Purified proteases were incubated with GST-Ufm1-HA at 37oC for 
1 hour and the products were separated by SDS-PAGE gel electropho-
resis (Invitrogen Ltd., UK). Protein bands were visualised by staining 
with Coomassie blue R-250.
Results
Since the original description of BHD in a multigeneration SA 
family, the pedigree has been extended to include family members 
in Canada, New Zealand and the UK. A condensed pedigree is 
shown in Fig. 1. A recent addition to the pedigree was affected 
individual VII:10, who was diagnosed at 31 years of age while 
resident in the UK. He presented with severe hip joint discomfort 
and pain that had increased progressively since the age of 13 years. 
Consistent with a diagnosis of BHD, his symptoms were confined 
to his hip joints; he was of normal stature, had no evidence of other 
deformity, and his general health was good. Specifically, he did not 
have joint hypermobility, cleft palate, or visual or hearing deficit. 
A skeletal survey revealed no evidence of abnormality other than 
in both of his hip joints, where the features were characteristic of 
BHD and associated OA was evident (Fig. 2). In keeping with the 
variable penetrance of the disorder, the progression of the clinical 
and radiological manifestations of VII:10 were less severe than 
those described for other family members. In addition, his father, 
although an obligate carrier of the BHD allele, was reported to be 
asymptomatic apart from mild joint discomfort at the age of 63 years.
BHD was previously linked to an 11-cM locus on chromosome 
4q35.[3] Subsequently, we fine-mapped the locus using proximal and 
distal markers D4S1535 and rs7663196, respectively. Recombination 
Table 1. Performance metrics for exome sequencing experiments
Sample ID
Total sequenced 
reads, n
Duplicate 
rate, %
Total aligned 
reads,* n
Proportion of reads 
mapped to coding exons, %
Variants located in coding exons 
and invariant splice sites, n
VII:9 295 153 748 43.5 163 283 145 58.9 20 750
VII:10 208 896 212 33.7 136 027 844 59.8 20 863
VI:24 239 488 548 57.4 99 711 251 62.5 20 591
*Following removal of duplicate sequences.
Fig. 2. Anteroposterior radiographs of the pelvis of (A) an unaffected adult 
and (B) a 31-year-old affected man (VII:10). In (B) the shortening and 
broadening of the femoral neck, coxa vara and displacement of the femoral 
head in the acetabulum are characteristic of BHD. The joint space narrowing, 
presence of marginal osteophytes, cyst formation and sclerosis are indicative 
of degenerative OA, which is more evident on the right.
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events (see individual VI:24, Fig. 1) reduced 
the size of the linked region from 3.34 Mb 
to 1.33 Mb and decreased the number of 
candidate genes from 25 to 16. To identify 
the BHD mutation, systematic sequence 
analysis of the coding exons and intron 
splice sites of CASP3, LRP2BP and UFSP2 
located in the linked region was conducted. 
This analysis identified a single novel 
heterozygous variant, c.868T>C, in UFSP2 
exon 8 (NM_018359.3) (Fig. 3, A).
To ensure that no additional candidate 
disease-causing variants were present within 
the linked interval, whole-exome sequencing 
was performed on three distantly related 
individuals (VII:9, VII:10 and VI:24). Exome 
sequencing performance metrics (Table 1) 
demonstrated that the hybridisation capture 
efficiencies, as determined by the percentage 
of sequence reads mapping to each exome, 
were comparable to those reported 
elsewhere.[8] To determine the proportion 
of target nucleotides that were sufficiently 
well sequenced to exclude the presence of 
non-reference nucleotides, read-depth 
analysis was performed. For two of the three 
sequenced individuals, >98% of target bases 
had a read depth that was ≥30×, which is a 
conservative read-depth metric that has been 
widely adopted by the diagnostic sequencing 
community[9] (Table 2).
Variants with a reported minor allele 
frequency <0.2 located within the fine-
mapped BHD locus (Chr4: 185  235  750 - 
186  570 521) were assessed for disease-
related pathogenicity. This yielded a filtered 
dataset comprising one variant in individual 
VII:9, one in VII:10 and four in VI:24. The 
single variant found in common between the 
affected individuals was the UFSP2 c.868T>C 
variant that had been identified by the initial 
sequencing screen. This c.868T>C variant 
was not identified in publicly accessible 
variant databases including dbSNP and the 
ESP5400 dataset. In addition, exon-based 
copy number analysis did not identify any 
dosage variants within the linked interval in 
any of the three individuals.
To explore familial segregation, all available 
members of the BHD family were genotyped 
for presence of the UFSP2 c.868T>C variant 
using PCR followed by restriction enzyme 
digestion with NdeI (see Fig. 3,  B for a 
representative genotyping gel and Fig. 1 for 
the genotypes). All 17 individuals with a 
confirmed diagnosis of BHD were hetero-
zygous for the c.868T>C mutation. There 
was evidence of non-penetrance in one 
obligate carrier (VII:4), and the mutation was 
found in two individuals (VII:8 and VII:14) 
in whom BHD had not been excluded or 
confirmed owing to their young age at time 
Fig. 3. (A) Sanger sequencing confirmation of the heterozygous UFSP2 c.868T>C (NM_018359.3) variant. 
The chromosome 4 human genome co-ordinate corresponds to build hg19. (B) A molecular assay was 
established for cascade screening of the extended family. A 341-bp PCR fragment was amplified and restricted 
with NdeI. PCR fragments of 219 bp and 122 bp indicate the presence of the mutant allele. (C) Alignment of 
partial protein sequences of UFSP2 for a range of multicellular organisms. The tyrosine (Y) residue at position 
290 is highly conserved and located in close proximity to the conserved protease Cys domain.
Fig. 4. In vitro biochemical analysis of UFSP2 function. (A) Increasing concentrations of purified UFSP2 WT 
correlated with increased cleavage of the HA tag from GST-Ufm1-HA. In contrast, even at high concentrations 
the enzymatic activity of UFSP2 BHD was abolished. (B) Increasing concentrations of UFSP2 BHD were 
incubated with constant concentrations of UFSP2 WT and GST-Ufm1-HA. No evidence for a dominant-
negative effect on the cleavage of GST-Ufm1-HA by UFSP2 WT was observed. ((-) = absence of protein.)
RESEARCH
562       July 2015, Vol. 105, No. 7
of consultation. Linkage analysis between 
BHD and the c.868T>C mutation generated a 
two-point (single marker) LOD score of 10.4 
(at θ = 0.0 and 80% penetrance).
The UFSP2 c.868T>C variant predicts a 
tyrosine to histidine substitution at position 
290 of the encoded protein, which is highly 
conserved across multiple species (Fig. 3, C). 
The effect of the p.Tyr290His substitution 
on UFSP2 protease activity was assayed in 
vitro as previously described by incubating 
recombinant purified mouse UFSP2 with 
Ufm1 that had been modified by the addition 
of an N-terminal GST tag and a C-terminal 
HA tag.[7] For this purpose, the heterologous 
mutation (c.844T>C, p.Tyr282His in the 
mouse) was inserted into the UFSP2 WT 
construct and expressed, and both the WT 
and UFSP2 BHD proteases were purified. 
Increasing concentrations of UFSP2 WT 
resulted in increased cleavage of the GST-
Ufm1-HA tag (Fig. 4, A). In contrast, UFSP2 
BHD did not cleave GST-Ufm1-HA, even at 
high concentrations. The processing activity 
of UFSP2 WT was not affected in the presence 
of increasing concentrations of UFSP2 BHD, 
indicating that UFSP2 BHD does not exert a 
dominant-negative effect at the level of Ufm1 
processing in vitro (Fig. 4, B).
Discussion
BHD is a unique Mendelian disorder that 
has to date been described in only a single 
SA family of European origin.[2] The size and 
structure of the pedigree enabled the initial 
mapping of the linked locus to Chr4q35. [3] 
However, this locus did not contain any 
obvious candidate genes. To reduce the 
burden of variant interpretation following 
mutation screening, we fine-mapped the 
region and thereby reduced the number 
of candidate genes from 25 to 16. Initial 
mutation screening of genes located within 
the locus by Sanger sequencing identified 
a unique UFSP2 c.868T>C variant. This 
variant was identified in all individuals tested 
who had a confirmed diagnosis of BHD, but 
there was evidence of non-penetrance of 
BHD in the pedigree. The segregation of this 
variant with BHD generated a LOD score of 
10.4 (at θ = 0.0 and 80% penetrance).
As no other forms of skeletal dysplasia 
had been mapped to the linked locus on 
Chr4q35, no other families with BHD had 
been reported and the UFSP2 c.868T>C 
variant appeared to be unique to the BHD 
family, independent verification that the 
variant was indeed the BHD mutation 
was not possible. We therefore undertook 
comprehensive exome analysis of the 
linked allele in three distantly related 
individuals. This analysis confirmed that T
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there were no other candidate disease-causing mutations in 
linkage disequilibrium with UFSP2 c.868T>C, suggesting that this 
variant is the BHD mutation. The identification of this mutation 
will enable diagnostic accuracy of BHD, aid predictive testing of 
at-risk family members, and underpin future longitudinal studies 
aimed at correlating the progression of radiological features with 
the onset of clinical symptoms. The cysteine protease encoded by 
UFSP2 is highly conserved and is homologous to a second cysteine 
protease, UFSP1, that has a similar C-terminal domain but a 
shorter N-terminal domain.[7] Neither protease shares sequence 
homology to other identified proteases. UFSP1 and UFSP2 have 
been shown previously to cleave two C-terminal residues (S101 
and C102) from the protein ubiquitin-fold modifier 1 (Ufm1).[7] 
Ufm1 is a post-translational modifier protein that is classified as a 
member of the family of ubiquitin-like proteins (Ubls). Following 
modification through an E1-E2-E3 multienzyme cascade, Ufm1 is 
attached to its target protein. The conjugation and deconjugation 
of target proteins by Ubls modulates their function and thereby 
the regulation of cellular processes.[10] In the Ufm1 modification 
pathway, Ufm1 is activated by either UFSP1 or UFSP2 to expose 
a C-terminal glycine residue.[7] Activated Ufm1 then reacts with 
Uba5 (E1-like enzyme) and is transferred to Ufc1 (E2-like enzyme) 
before being transferred to its target protein by Ufl1 (E3-like 
enzyme). At present, the full repertoire of Ufm1 target proteins 
remains to be identified. Although there are currently no reported 
studies detailing the tissue specificity or time course of UFSP2 
expression, analysis of multiple mouse tissues has revealed that 
Ufm1 expression is abundant in protein-secreting cells.[11] Further, 
there is increasing evidence that the Ufm1 pathway has a role in 
the regulation of endoplasmic reticulum (ER) stress responses. [12] 
Interestingly, ER stress is a recognised pathogenic mechanism 
underlying a number of forms of osteochondrodysplasia, and the 
ER stress response has been proposed as a therapeutic target for 
such disorders.[13] This reported evidence therefore suggests a 
putative mechanistic link between the Ufm1/UFSP2 pathway and 
the BHD phenotype.
Alignment of multiple UFSP2 protein sequences from different 
multicellular organisms, including plants and animals, demonstrated 
that the p.Tyr290 residue has been conserved for at least 1.6 
billion years.[14] In an in vitro assay we found that purified mouse 
UFSP2 containing the mouse equivalent of the p.Tyr290His BHD 
substitution did not cleave Ufm1, even at high concentrations. Lack 
of activity of the mutated protease is consistent with predictions made 
from the crystal structure of UFSP2 that the p.Tyr290 amino acid is 
a crucial residue within the UFSP2 active site.[15] In this in vitro assay, 
however, the mutated UFSP2 did not appear to exert a dominant-
negative effect. Confirmation of the functional consequences of 
the BHD mutation on the Ufm1/UFSP2 pathway therefore requires 
further investigation.
Conclusion
In summary, genetic and functional data support that UFSP2 
c.868T>C is the mutation causing BHD. The facile PCR-based assay 
that we have described could be used to confirm the diagnosis of 
BHD, or for presymptomatic testing of members of the extended 
BHD family.
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